Industry veteran joins Auxilium Pharmaceuticals

Adrian Adams succeeds Armando Anido at the US firm

Auxilium Pharmaceuticals, a specialist biopharmaceutical company based in Malvern, PA, US, has appointed Adrian Adams as chief executive and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down and has resigned as a member of the Board. Adams will also succeed him on the Board.

Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.

Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.

Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Drug Delivery

Palvella's QTORIN achieves positive Phase III results

Working in collaboration with MedPharm, the biopharma company announced positive topline results from its Phase 3 SELVA study of QTORIN rapamycin, paving the way for the company to prepare for commercial-scale manufacturing
Manufacturing

Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line

German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals
Research & Development

Coriolis Pharma opens US headquarters and laboratory at Research Triangle Park in North Carolina

Biopharmaceutical services specialist Coriolis Pharma has launched its first US base at the Alexandria Centre for Advanced Technologies, offering North American clients direct access to formulation development, particle analysis and drug product characterisation services
Subscribe now